Chemistry:Decernotinib
From HandWiki
Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also had the name VX-509 in development phase. It is an experimental drug with high selectivity for JAK3, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). It has been studied in clinical trials at Vertex Pharmaceuticals,[1] and while it was not approved for clinical use it continues to be used for research.[2][3][4]
References
- ↑ "Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases". Journal of Medicinal Chemistry 58 (18): 7195–216. September 2015. doi:10.1021/acs.jmedchem.5b00301. PMID 26230873.
- ↑ "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research". RMD Open 6 (3). November 2020. doi:10.1136/rmdopen-2020-001374. PMID 33188136.
- ↑ "Current jakinibs for the treatment of rheumatoid arthritis: a systematic review". Inflammopharmacology 29 (3): 595–615. June 2021. doi:10.1007/s10787-021-00822-x. PMID 34046798.
- ↑ "Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors". International Immunopharmacology 111. October 2022. doi:10.1016/j.intimp.2022.109095. PMID 35926270.
 |  |
